Essity AB stock (SE0009922164): CEO buys SEK 2.8M in shares

Essity AB CEO Ulrika Kolsrud purchased 11,308 Class B shares on May 11 at SEK 247.40 per share, totaling SEK 2.8 million, according to the Swedish Financial Supervisory Authority as of May 12, 2026. This insider buy comes as the hygiene products leader maintains steady performance in tissue and health sectors.

As of: 12.05.2026

By the editorial team – specialized in equity coverage.

Essity AB: core business model

Essity AB leads in sustainable hygiene and health solutions, producing tissue, incontinence products, and professional hygiene items globally. The company operates through divisions like Tissue, which includes brands such as Tork and Lotus, and Health & Medical, focusing on wound care and compression. With production in over 30 countries, Essity emphasizes innovation in eco-friendly materials, according to its investor relations page as of 2026.

Essity's model centers on consumer and professional segments, with a strong push toward circular economy practices. Revenue stems from everyday essentials, making it resilient to economic cycles. US investors note its exposure via North American sales, competing with Procter & Gamble in tissue markets.

Main revenue and product drivers for Essity AB

Tissue represents about 50% of sales, driven by retail brands and away-from-home products like Tork dispensers used in US offices and healthcare. Incontinence and wound care contribute through medical-grade items sold to hospitals and pharmacies across North America. Professional hygiene adds via soaps and dispensers, per company reports.

Growth drivers include premiumization and sustainability, with biomass energy shifts at French sites accelerating decarbonization, as noted in recent updates. For US investors, Essity's 10%+ North American revenue share ties it to consumer spending trends.

Industry trends and competitive position

The global hygiene market grows at 5% annually, fueled by aging populations and hygiene awareness post-pandemic. Essity holds top spots in Europe and expanding US presence against Kimberly-Clark and Georgia-Pacific. Its sustainability edge, like biomass at production sites, aligns with ESG demands from US funds.

Why Essity AB matters for US investors

Listed on Nasdaq Stockholm, Essity offers US investors access to stable defensive plays via ADRs or direct trading. Its North American tissue and health sales link to US healthcare spending, projected to rise 5.4% in 2026 per sector data. Defensive qualities suit portfolios amid volatility.

Conclusion

CEO Ulrika Kolsrud's recent share purchase underscores internal confidence in Essity AB's hygiene leadership. With solid revenue drivers and sustainability initiatives, the company maintains relevance for US investors seeking defensive exposure to health and tissue markets. Market dynamics will shape near-term performance.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.